The orthotopic MISTRG model has allowed us to uncover a previously unappreciated dependence of a subset of DLBCL on the IL‐6 signaling pathway, which can be exploited therapeutically with a specific monoclonal antibody that is approved for other unrelated indications. Here, IL6 is linked to diffuse large B-cell lymphoma.